Beijing Yongxuan Science and Technology

Beijing Yongxuan Science and Technology is a China-based biotechnology company dedicated to the discovery and development of innovative small molecule drugs for the treatment of cancer. The company focuses on high-value targets within the DNA damage response (DDR) and RAS signaling pathways, which are critical drivers in various malignancies. Its lead research programs include inhibitors of ubiquitin-specific protease 1 (USP1) and KRAS G12D, designed to overcome resistance mechanisms in solid tumors such as ovarian and pancreatic cancers. Yongxuan leverages a robust internal R&D platform to accelerate the transition of candidates from discovery to clinical evaluation. The company is positioned as an emerging player in the precision oncology space within the Chinese biotech ecosystem.